banner2

Getting started
Cbz-L-Tryptophan

Cbz-L-Tryptophan - China Manufacturers, Factory, Suppliers

Cbz-L-Tryptophan, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Z-Trp-OH CAS 7432-21-5 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Z-Trp-OH CAS 7432-21-5 Nα-Cbz-L-Tryptophan Purity >99.0% (HPLC) Factory
Read More

Z-Trp-OH CAS 7432-21-5 Nα-Cbz-L-Tryptophan Purity >99.0% (HPLC) Factory

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

banner4

Top Selling Products

Related Blog
Reviews

Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021)-Shanghai Ruifu Chemical Co., Ltd. participated in the exhibition

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021) was held on September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. Adhering to...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...

2022.12.18 20:22:51
2022.11.15 18:57:07
2022.08.07 23:18:18
2022.04.19 00:18:33
2022.01.09 22:25:46
2021.10.20 06:28:25

related search